Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | KEYNOTE-204: pembrolizumab vs brentuximab vedotin in R/R cHL

John Kuruvilla • 8 Dec 2020
ASH 2020
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Pembrolizumab
KEYNOTE-204

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, discusses the patient-reported outcomes from the Phase III KEYNOTE-204 trial (NCT02684292) of pembrolizumab versus brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (cHL) patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from John Kuruvilla

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:06
Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL
John Kuruvilla • 12 Dec 2022
1:18
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
John Kuruvilla • 12 Dec 2022
0:49
Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla • 12 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals